Literature DB >> 1815048

Semiparametric analysis of non-steady-state pharmacodynamic data.

D Verotta1, L B Sheiner.   

Abstract

We present an approach to the analysis of pharmacodynamic (PD) data arising from non-steady-state experiments, meant to be used when only PD data, not pharmacokinetic (PK) data, are available. The approach allows estimation of the steady-state relationship between drug input and effect. The analysis is based on a model describing the time dependence of drug effect (E) on (unobserved) drug concentration (Ce) in an hypothetical effect compartment. The model consists of (i) a known model for the input rate of drug I(t), (ii) a parametric model; L(t, alpha) (a function of time t, and vector of parameters alpha), relating I to an observed variable X, (iii) a nonparametric model relating X to E. Ce is proportional to X. X (t) is given by I(t) * L(t, alpha)/AL, where L(t, alpha) = e-alpha 1t * sigma k m = 1 alpha 2k e-alpha 2k + 1t, sigma k m = 1 alpha 2k = 1, AL = integral of 0 infinity L(t) dt, and * indicates convolution. The nonparametric model relating X to E is a cubic spline, a function of X and a vector of (linear) parameters beta. The values of alpha and beta are chosen to minimize the sum of squared residuals between predicted and observed E. We also describe a similar model, generalizing a previously described one, to analyze PK/PD data. Applications of the approach to different drug-effect relationships (verapamil-PR interval, hydroxazine-wheal and flare, flecainide and/or verapamil-PR, and left ventricular ejection fraction) are reported.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815048     DOI: 10.1007/BF01080874

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  17 in total

1.  Theoretical and computational basis for drug bioavailability determinations using pharmacological data. II. Drug input in equilibrium to response relationships.

Authors:  V F Smolen
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

2.  Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and procedures.

Authors:  V F Smolen
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

3.  Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.

Authors:  J B Schwartz; D Verotta; L B Sheiner
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

4.  A system approach to pharmacodynamics. I: Theoretical framework.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharm Sci       Date:  1988-01       Impact factor: 3.534

5.  Semiparametric approach to pharmacokinetic-pharmacodynamic data.

Authors:  D Verotta; S L Beal; L B Sheiner
Journal:  Am J Physiol       Date:  1989-04

6.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

Authors:  J D Unadkat; F Bartha; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

7.  Kinetics of interaction between drugs and biological systems.

Authors:  G Segre
Journal:  Farmaco Sci       Date:  1968-10

8.  The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine.

Authors:  F E Simons; K J Simons; E M Frith
Journal:  J Allergy Clin Immunol       Date:  1984-01       Impact factor: 10.793

9.  The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance.

Authors:  J L Holtzman; D Finley; L Mottonen; D A Berry; B P Ekholm; D C Kvam; R L McQuinn; A M Miller
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

10.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

View more
  10 in total

Review 1.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

2.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

3.  New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.

Authors:  G Stagni; A M Shepherd; Y Liu; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

4.  Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Authors:  Mario González-Sales; Fahima Nekka; Mario Tanguay; Pierre-Olivier Tremblay; Jun Li
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

Review 5.  Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications.

Authors:  Jean-Xavier Mazoit
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

Review 7.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

8.  Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.

Authors:  M Gumbleton; S Oie; D Verotta
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

9.  Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.

Authors:  N B Modi; P Veng-Pedersen
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

Review 10.  Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.

Authors:  Belén P Solans; María Jesús Garrido; Iñaki F Trocóniz
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.